The effects of rutin flavonoid on type 2 diabetes mellitus

The effects of rutin flavonoid supplement on glycemic status, lipid profile, plasma atherogenic index, brain derived neurotropic factor (BDNF), some serum inflammatory biomarkers and oxidative stress in patients with type 2 diabetes mellitus

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20151128025274N5

Enrollment

Registered

2020-12-30

Start date

2021-01-20

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus. Type 2 diabetes mellitus

Interventions

Intervention 1: Intervention group: Every day, one tablet of 1 g rutin (containing 500 mg of pure rutin and 500 mg other compounds include di-calcium phosphate, microcrystalline cellulose, plant cellu

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Willingness to participate in the study People between 20 to 60 years old in both sexes Over at least 2 years from time of diagnosis of type 2 diabetes mellitus Body mass index (BMI) less than 35 (BMI = 35) Glycosylated hemoglobin (HbA1c) between 6.5 to 11%

Exclusion criteria

Exclusion criteria: Reluctance of patients to participate in the study Developing complications from diabetes such as kidney failure Diabetic patients taking insulin Thyroid disease Anemia Pregnancy, lactation Traveling more than 2 weeks Smokers Use of other dietary supplements, probiotics and anti-inflammatory drugs Use of any antioxidant supplements in the last 3 months Use of immunosuppressive drugs Following of special diets other than the diet specific to diabetic patients Change of diet or decide to lose weight

Design outcomes

Primary

Measure	Time frame
Fasting blood sugar. Timepoint: Before and after the intervention. Method of measurement: Using enzymatic kit method.	—

Secondary

Measure	Time frame
Insulin. Timepoint: Before and after the intervention. Method of measurement: ELISA.;HbA1C. Timepoint: Before and after the intervention. Method of measurement: By HPLC method and with Ds5 device.;HOMA -IR. Timepoint: Before and after the intervention. Method of measurement: [FPG (mmol / l x FPI (FIU/ml)] / 22.5.;QUICKi. Timepoint: Before and after the intervention. Method of measurement: 1 / [log (I0) + log (G0)] ISQUICKi.;Plasma atherogenic index. Timepoint: Before and after the intervention. Method of measurement: log TG/HDL.;HDL-c. Timepoint: Before and after the intervention. Method of measurement: Using enzymatic kit method.;Triglyceride. Timepoint: Before and after the intervention. Method of measurement: Using enzymatic kit method.;LDL.C. Timepoint: Before and after the intervention. Method of measurement: Using enzymatic kit method.;Total cholestrol. Timepoint: Before and after the intervention. Method of measurement: Using enzymatic kit method.;IL-6. Timepoint: Before and after the intervention. Method of measurement: ELISA.;TAC. Timepoint: Before and after the intervention. Method of measurement: ELISA.;MDA. Timepoint: Before and after the intervention. Method of measurement: ELISA.;BDNF. Timepoint: Before and after the intervention. Method of measurement: ELISA.	—

Measure

Time frame

Insulin. Timepoint: Before and after the intervention. Method of measurement: ELISA.;HbA1C. Timepoint: Before and after the intervention. Method of measurement: By HPLC method and with Ds5 device.;HOMA -IR. Timepoint: Before and after the intervention. Method of measurement: [FPG (mmol / l x FPI (FIU/ml)] / 22.5.;QUICKi. Timepoint: Before and after the intervention. Method of measurement: 1 / [log (I0) + log (G0)] ISQUICKi.;Plasma atherogenic index. Timepoint: Before and after the intervention. Method of measurement: log TG/HDL.;HDL-c. Timepoint: Before and after the intervention. Method of measurement: Using enzymatic kit method.;Triglyceride. Timepoint: Before and after the intervention. Method of measurement: Using enzymatic kit method.;LDL.C. Timepoint: Before and after the intervention. Method of measurement: Using enzymatic kit method.;Total cholestrol. Timepoint: Before and after the intervention. Method of measurement: Using enzymatic kit method.;IL-6. Timepoint: Before and after the intervention. Method of measurement: ELISA.;TAC. Timepoint: Before and after the intervention. Method of measurement: ELISA.;MDA. Timepoint: Before and after the intervention. Method of measurement: ELISA.;BDNF. Timepoint: Before and after the intervention. Method of measurement: ELISA.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHadi Bazyar

Ahvaz University of Medical Sciences

hadibazyar2015@gmail.com+98 61 3333 0747

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026